22
Ibogaine in the treatment of chronic hepatitis C Howard S. Lotsof. President Dora Weiner Foundation Staten Island, NY http://www.doraweiner.org Invitational Ibogaine forum Warsaw 2007 Wednesday 16 May Hotel Sofitel Victoria

Antiviral Effects of Ibogaine and Hepatitis - Lotsof

Embed Size (px)

Citation preview

Page 1: Antiviral Effects of Ibogaine and Hepatitis - Lotsof

Ibogaine in the treatment ofchronic hepatitis C

Howard S. Lotsof.President

Dora Weiner FoundationStaten Island, NY

http://www.doraweiner.org

Invitational Ibogaine forumWarsaw 2007

Wednesday 16 MayHotel Sofitel Victoria

Page 2: Antiviral Effects of Ibogaine and Hepatitis - Lotsof

Tabernanthe ibogasource of ibogaine

Found in West African rain forests

Page 3: Antiviral Effects of Ibogaine and Hepatitis - Lotsof

Purified Ibogaine HCl

Courtesy Jason CallanPresident and FounderEthnogarden Botanicalwww.ethnogarden.com

Page 4: Antiviral Effects of Ibogaine and Hepatitis - Lotsof

Ibogaine HClpharmaceutical grade

99.4% purity

Page 5: Antiviral Effects of Ibogaine and Hepatitis - Lotsof

1973: Non A, Non B hepatitis is described

1989: HCV RNA virus identified

1990: Anti HCV effects of ibogaine

reported

2005: Patent application for ibogaine to

treat chronic HCV filed

Hepatitis C (HCV)timeline

Page 6: Antiviral Effects of Ibogaine and Hepatitis - Lotsof

Most common viral infection in the

United States

New infections per year 1990 - 242,000New infections per year 2001 - 25,000New infections per year 2004 - 25,000Greater than 75% of IVDUs test

positive

HCV infection

Page 7: Antiviral Effects of Ibogaine and Hepatitis - Lotsof

1. The discovery of ibogaine’s use in treating both chemical dependence and HCV was by ibogaine activist advocates who were themselves treated or self-treated with ibogaine.

2. Scientific research followed patent development in the treatment of chemical dependence and it is hoped the same will be true for ibogaine related HCV research.

Science follows patent development

Page 8: Antiviral Effects of Ibogaine and Hepatitis - Lotsof

1. Rapid method for interrupting the narcotic addiction syndrome, US 4,499,096 (1985)

2. Rapid method for interrupting the cocaine and amphetamine abuse syndrome US 4,587,243 (1986)

3. Rapid method for attenuating the alcohol dependency syndrome, US 4,957,523 (1989)

4. Rapid method for interrupting or attenuating the nicotine/tobacco dependency syndrome, US 5,026,697 (1991)

5. Rapid method for interrupting or attenuating poly-drug dependency syndromes, US 5, 124,994 (1992)

Ibogaine Patents

Page 9: Antiviral Effects of Ibogaine and Hepatitis - Lotsof

1. Broad ranging claims of ibogaine to treat multiple forms of chemical doubted

2. Over time, all claims for chemical dependence have been confirmed by research

a) Opioids,

b) stimulants,

c) Alcohol

d) nicotine

Research follows skepticism

Page 10: Antiviral Effects of Ibogaine and Hepatitis - Lotsof

Opioids

Page 11: Antiviral Effects of Ibogaine and Hepatitis - Lotsof

Cocaine

Page 12: Antiviral Effects of Ibogaine and Hepatitis - Lotsof

Alcohol

Page 13: Antiviral Effects of Ibogaine and Hepatitis - Lotsof

Nicotine

Page 14: Antiviral Effects of Ibogaine and Hepatitis - Lotsof

• International Coalition for Addict Self-Help (ICASH) 1989

• Dutch Addict Self-Help (DASH) 1990

• Ibogaine Underground 2004

Ibogaine activist organizations play

role in ibogaine HCV research

Page 15: Antiviral Effects of Ibogaine and Hepatitis - Lotsof

HCV patent application

Page 16: Antiviral Effects of Ibogaine and Hepatitis - Lotsof

Example 1 Report

A thirty-three year old male diagnosed with HCV and using 1/4 gram of heroin a day was administered 25 mg/kg ibogaine HCl. Following administration of ibogaine heroin use ceased along with swelling of the liver and pain in the area of the liver.

Page 17: Antiviral Effects of Ibogaine and Hepatitis - Lotsof

Example 2 Liver enzyme values reduced

by 14 mg/kg ibogaine

Enzyme Pre Post

ALT 410 50

AST 201 25

GGT 155 33

Page 18: Antiviral Effects of Ibogaine and Hepatitis - Lotsof

Example 3

A sixty year old male testing positive for HCV RNA genotype I, administered the following dose regimens of ibogaine HCl. Subject weighed 79 kg. Doses administered were as total doses and not mg/kg. Day 1: 10 mg, Day 2: 20 mg, Day 3: 20 mg, Day 4: 30 mg, Day 5: 50 mg, Day 6: 75 mg, Day 8: 100 mg.Day 10: 150 mg, Day 14: 300 mg. HCV RNA UL/ml was reduced from 780,000 to 644,000, Pretreatment Alkaline Phosphatase was 99, AST was 103 and ALT 195. Post treatment Alkaline Phosphatase was 88, AST 89 and ALT 127. An additional 250 mg ibogaine HCl reduced HCV RNA UL/ml to 154,000. Further testing showed continued reduction to HCV RNA UL/ml 78,200

Page 19: Antiviral Effects of Ibogaine and Hepatitis - Lotsof

Example. 4 A forty-two year old female testing positive for HCV RNA type 3. RNA IU/ml was 12,600,000. Subject was administered a total of 27 mg/kg ibogaine HCl in the following regimen:

6 x 2 mg/kg1 x 12 mg/kg1 x 3 mg/kg

HCV RNA IU/ml was reduced to 50,100. Prior to ibogaine treatment patient’s urine was dark and stool light. Post treatment color of urine and stool returned to normal.

Page 20: Antiviral Effects of Ibogaine and Hepatitis - Lotsof

ReviewPreliminary Examples Reporting

Reduction Viral Load by ibogaine

Subject Pre Post

3 780,000 78,200

4 12,600,00 50,100

Page 21: Antiviral Effects of Ibogaine and Hepatitis - Lotsof

Encouraging results

1. Repetitive low dosing with ibogaine provided continuous depression of viral load.

2. Genotype 3 appears highly responsive in keeping with results of interferon riboviron therapy.

3. Continued reduction in viral load after stopping of ibogaine therapy observed.

4. Less toxic than current HCV therapies.

Page 22: Antiviral Effects of Ibogaine and Hepatitis - Lotsof

Future development

1. Interest of pharmaceutical companies with experience in development of HCV drugs.

2. Preclinical confirmation of efficacy if possible.

3. Phase I/II clinical studies to confirm findings and establish preferred dose regimen.